Catalog No.S4709 Synonyms: Xalatan, PhXA41, PHXA-41
Molecular Weight(MW): 432.59
Latanoprost is a prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral outflow and thereby reduces intraocular pressure.
Purity & Quality Control
Choose Selective Immunology & Inflammation related Inhibitors
|Description||Latanoprost is a prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral outflow and thereby reduces intraocular pressure.|
Latanoprost functioned as both an indirect activator of AMP-activated protein kinase and a selective retinoid X receptor α (RXRα) antagonist able to selectively antagonise the transcription of a RXRα/peroxisome proliferator-activated receptor γ heterodimer. Latanoprost induced morphological abnormality and viability decline of HCS cells in vitro. It induces cell cycle arrest of HCS cells. Latanoprost induces abnormal changes of plasma membrane, DNA fragmentation and ultrastructural abnormality of HCS cells. Caspase activation in HCS cells is also activated by Latanoprost treatment. Latanoprost induces MTP disruption and quantitative changes of mitochondrion-associated pro-apoptotic regulators in HCS cells. Latanoprost is effective in inhibiting adipogenesis, reducing lipogenesis, promoting fatty acid oxidation and enhancing GLUT4 translocation and glucose uptake both in adipocytes and myotubes.
|In vivo||Latanoprost, a clinical drug for treating primary open-angle glaucoma and intraocular hypertension, effectively ameliorates glucose and lipid disorders in two mouse models of type 2 diabetes. Its treatment improves glucose tolerance. Chronic administration of latanoprost decreases serum lipids and enhances insulin signalling in white adipose tissue and skeletal muscle. It effectually activates AMPK and regulates glucose and lipid metabolism-relevant genes in diabetic mice.|
|Synonyms||Xalatan, PhXA41, PHXA-41|
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03331770||Completed||Primary Open-angle Glaucoma||Laboratorios Poen||January 6 2017||Phase 4|
|NCT02623738||Completed||Primary Open Angle Glaucoma|Ocular Hypertension||Santen Pharmaceutical Co. Ltd.||December 6 2015||Phase 2|Phase 3|
|NCT03284853||Recruiting||Open Angle Glaucoma|Ocular Hypertension||Aerie Pharmaceuticals||September 5 2017||Phase 3|
|NCT03067415||Recruiting||Glaucoma Primary Open Angle|Ocular Hypertension||Chong Kun Dang Pharmaceutical||March 30 2017||Phase 2|
|NCT02622334||Completed||Glaucoma||Hoffmann-La Roche||December 29 2015||Phase 1|
|NCT03419975||Recruiting||Primary Open-angle Glaucoma|Ocular Hypertension||Taejoon Pharmaceutical Co. Ltd.||April 26 2016||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.